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Background: Youth with serious mental illness may experience improved psychiatric stability with second
generation antipsychotic (SGA) medication treatment, but unfortunately may also experience unhealthy weight
gain adverse events. Research on weight loss strategies for youth who require ongoing antipsychotic treatment is
quite limited. The purpose of this paper is to present the design, methods, and rationale of the Improving
Metabolic Parameters in Antipsychotic Child Treatment (IMPACT) study, a federally funded, randomized trial
comparing two pharmacologic strategies against a control condition to manage SGA-related weight gain.
Methods: The design and methodology considerations of the IMPACT trial are described and embedded in a
description of health risks associated with antipsychotic-related weight gain and the limitations of currently
available research.
Results: The IMPACT study is a 4-site, six month, randomized, open-label, clinical trial of overweight/obese youth
ages 8–19 years with pediatric schizophrenia-spectrum and bipolar-spectrum disorders, psychotic or non-psychotic
major depressive disorder, or irritability associated with autistic disorder. Youth who have experienced clinically
significant weight gain during antipsychotic treatment in the past 3 years are randomized to either (1) switch
antipsychotic plus healthy lifestyle education (HLE); (2) add metformin plus HLE; or (3) HLE with no medication
change. The primary aim is to compare weight change (body mass index z-scores) for each pharmacologic
intervention with the control condition. Key secondary assessments include percentage body fat, insulin resistance, lipid
profile, psychiatric symptom stability (monitored independently by the pharmacotherapist and a blinded evaluator),
and all-cause and specific cause discontinuation. This study is ongoing, and the targeted sample size is 132 youth.
Conclusion: Antipsychotic-related weight gain is an important public health issue for youth requiring ongoing
antipsychotic treatment to maintain psychiatric stability. The IMPACT study provides a model for pediatric research on
adverse event management using state-of-the art methods. The results of this study will provide needed data on risks
and benefits of two pharmacologic interventions that are already being used in pediatric clinical settings but that have
not yet been compared directly in randomized trials.
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In recent years, there has been growing concern about
potential harm caused by second-generation anti-
psychotic (SGA) treatment of children and adolescents.
SGA metabolic adverse effects include weight gain,
dyslipidemia, increased blood pressure, and hypergly-
cemia/new onset diabetes [1-4]. Children and adoles-
cents, especially those who are antipsychotic-naïve, are
at greater risk for unhealthy weight gain adverse events
than adults [3,5,6], and they often gain over 7% baseline
weight within the first few months of treatment [1,7,8].
Providers may utilize pharmacologic (e.g. switch to a dif-
ferent SGA) and/or non-pharmacologic (e.g. diet/nutri-
tion counseling) strategies to reduce adverse metabolic
effects, but these interventions have not been systemat-
ically studied in pediatric patients [9]. Alternatively, pre-
scribers may consider use of first-generation or “typical”
antipsychotic medications. Some typical antipsychotic
medications are associated with lower risk of obesity re-
lated adverse events compared to several SGA’s [3].
However, these older medications are associated with a
higher risk of acute extrapyramidal adverse events and in-
voluntary abnormal movements [6]. Of particular concern
is the increased risk of tardive dyskinesia, a potentially ir-
reversible movement disorder that typically manifests after
long-term treatment.
This article reports on the rationale, design, and
methods of a federally funded, multi-site clinical trial fo-
cused on management of metabolic adverse effects
among youth who require ongoing antipsychotic medi-
cation treatment to maintain psychiatric stability. The
Improving Metabolic Parameters in Antipsychotic Child
Treatment (IMPACT) study is an open-label, 6-month
trial, in which overweight and obese youth with SGA-
induced weight gain are randomized to treatment with
either (1) switch antipsychotic medication to one that is
lower risk for metabolic side effects + healthy lifestyle
education (HLE); (2) add metformin + HLE; or (3) HLE
alone (control condition). This study began enrollment
in 2008 and is being conducted at Johns Hopkins Univer-
sity, University of Maryland, University of North Carolina,
and The Zucker Hillside Hospital.
Rationale for study
SGA medications are often used to treat chronic and
serious mental illness in adults and youth. Current FDA
approved pediatric indications include irritability associ-
ated with autism, acute psychosis in schizophrenia, and
mixed and manic episodes in bipolar disorder [10].
SGAs may cause significant adverse effects, but ongoing
treatment may be required to achieve or maintain psy-
chiatric stability. Three general strategies to manage
SGA-induced weight gain include (1) switch antipsychotic
medication to another antipsychotic with lower metabolicrisk [11]; (2) add a pharmacologic weight loss agent [12];
and/or (3) add a non-pharmacologic weight loss interven-
tion [13]. While these strategies are currently utilized in
clinical settings, there is very limited pediatric data to
guide clinicians on the risks and benefits of these strat-
egies [9]. Randomized studies testing an antipsychotic
switch strategy have only been conducted in adults, show-
ing some reductions in weight and metabolic parameters
[11,14]. Non-pharmacologic weight loss interventions for
adult antipsychotic-related weight gain have had some
limited success, yet no such studies exist in pediatric pa-
tients [9,13]. Further, no pediatric RCT’s have compared
strategies to manage antipsychotic induced weight gain. In
contrast, two adult studies have been conducted that dir-
ectly compared different weight loss strategies in anti-
psychotic treated patients. Wu et al. [15] compared
metformin, healthy lifestyle, and the combination of met-
formin plus healthy lifestyle, and Stroup et al. [16] com-
pared healthy lifestyle intervention versus healthy lifestyle
plus switch to a lower cardiometabolic risk antipsychotic.
To date, no three-arm study of weight loss options for
antipsychotic treated patients who experienced relevant
weight gain exists, and no study has directly compared
addition of a weight loss medication with a switch to a
lower risk antipsychotic and healthy lifestyle instructions.
Unhealthy weight gain caused by pediatric SGA treat-
ment is a major public health concern because child-
hood obesity is a risk factor for cardiovascular disease
and type 2 diabetes. The prospective Harvard Growth
Study reported that being overweight in adolescence is a
more powerful predictor of morbidity from coronary
heart disease than being overweight as an adult [17]. A
large population cohort epidemiologic study reported
that the risk for any adult coronary heart disease was
positively associated with body mass index (BMI) at age
7–13 for boys and 11–13 for girls, and the risk increased
across the entire BMI distribution [18]. Obesity is also
the most important risk factor for development of
pediatric type 2 diabetes [19]. Sinha et al. [20] reported a
high prevalence of glucose intolerance (25% of children;
21% of adolescents) and 4% with silent type 2 diabetes
among a sample of obese youth. Although youth treated
with SGAs seldom develop diabetes because of their
large insulin reserve, they often develop insulin resist-
ance and dyslipidemia, which markedly enhance the risk
for long-term morbidity and mortality. Unfortunately,
childhood obesity often persists into adulthood [21-23].
For example, in the Bogalusa Heart study, 77% of obese
children were obese as young adults [24].
IMPACT is the first pediatric study to systematically
examine more than one active treatment for SGA in-
duced weight gain using a longitudinal design and state-
of-the-art methodology. The results of this study will
guide future clinical interventions to provide the safest
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early onset schizophrenia spectrum, pediatric bipolar
disorder, severe mood dysregulation, psychotic or non-
psychotic major depressive disorder, or irritability associ-
ated with autistic disorder.
Rationale for intervention arms
Switch antipsychotic medication
Several expert consensus statements [3,25,26] recom-
mend switching of the antipsychotic to a lower meta-
bolic risk agent as an option to manage antipsychotic
induced weight gain. This option has the advantage of
removing the offending agent and providing ongoing
treatment at therapeutic doses (as opposed to the strat-
egy of lowering the dose). However, there is a potential
risk for psychiatric de-stabilization, even with a careful
cross-over titration. A 2010 Cochrane review of four
randomized controlled trials (RCTs) of antipsychotic
switch versus continued treatment in adults concluded
that switching to a lower risk agent may be an effective
strategy to manage metabolic side effects, resulting in
weight loss and improved fasting blood glucose [11]. Of
note, there was no difference in adverse events (includ-
ing or excluding metabolic adverse events) in the switch
versus continuation antipsychotic groups in these pre-
liminary studies.
Selection of an appropriate switch agent for the
IMPACT trial was challenging because of rapid changes
in available SGAs. Initially, aripiprazole was selected as the
switch agent, based on promising data from both adult
and pediatric psychiatry studies that this agent had a lower
risk of adverse metabolic events [27,28]. This information
lead to significant increases in off-label prescribing, even
before pediatric data from controlled efficacy and safety
studies were available. Aripiprazole quickly became a first
line prescribed antipsychotic medication. Unfortunately,
evidence emerged that, at least among antipsychotic naïve
patients, aripiprazole can also be associated with signifi-
cant weight gain. For example, in a non-randomized in-
ception cohort study, antipsychotic-naïve youth prescribed
aripiprazole experienced a mean weight gain of 4.4 kg at
12 weeks, which was less than the weight gain of 8.4 kg on
olanzapine, 6.1 kg on quetiapine and 5.3 kg on risperi-
done, but significantly greater than the 0.19 kg weight gain
experienced by non-antipsychotic treated youth [1]. Thus,
we required an appropriate alternative switch medication
for youth who had either inadequate prior response to
aripiprazole and/or weight gain on this medication.
Molindone was selected as an alternative switch agent.
This choice was based largely on the results of a double
blind RCT for youth with schizophrenia or schizoaffective
disorder in which weight gain at 8 weeks was greatest for
olanzapine (6.1 kg), followed by risperidone (3.6 kg), and
molindone (0.3 kg) [29]. Shortly after being added tothe IMPACT study switch arm, however, molindone was
removed from the market by the manufacturer for non-
safety reasons. Only one participant received this medi-
cation, and the parent elected to discontinue treatment
since the child could not stay on the medication after
the study was completed.
Perphenazine was selected to replace molindone as the
second antipsychotic switch medication. There are no
modern, placebo-controlled, randomized trials of per-
phenazine in youth. The one published study [30] has
too many methodological problems to be interpretable.
Perphenazine was selected based on the CATIE study,
an adult schizophrenia trial that compared perphenzine
to olanzapine, quetiapine, and risperidone treatment
[31]. Perphenazine had a better profile in terms of drug-
induced weight gain and metabolic changes compared to
the SGA’s, but had a higher discontinuation rate for
extrapyramidal side effects. To address the potential risk
of EPS, we provided prophylactic treatment with benz-
tropine for youth prescribed > 8 mg perphenazine. EPS
symptoms were monitored at each visit (refer to Table 1
for assessment schedule). For all participants, the protocol
allows for treatment of emergent EPS with benztropine or
trihexyphenidyl and treatment of akathisia with propran-
olol, lorazepam, or clonazepam.
Ziprasidone is associated with lower metabolic adverse
effects, but it was not chosen as a switch agent because
it has a relatively greater risk for QTc prolongation com-
pared to other antipsychotic medication options [3].
Ziprasidone treatment would require greater cost and
time for ECG monitoring to address potential increased
risk of arrhythmias. A recent study indicates that this
risk is likely not clinically relevant [32], however, ECG
monitoring continues to be done as part of standard of
care for ziprasidone treatment.
Antipsychotic switch to a lower risk agent, either
aripiprazole or perphenazine, represents a single weight
loss strategy in IMPACT. The analysis will not distin-
guish between aripiprazole and perphenazine or examine
any differences between them, except descriptively, be-
cause the selection of the switch medication is non-
random, and based on prior treatment history.
Add metformin
The selection of a pharmacologic weight loss agent
was based on pediatric safety/tolerability, feasibility,
and efficacy data specifically for SGA-induced weight
gain. Four medications were considered: sibutramine,
orlistat, topiramate, and metformin. Sibutramine and
orlistat received FDA approval for treatment of obese ado-
lescents (orlistat for youth ≥ 12 years old; sibutramine for
youth ≥16) [33]. Sibutramine is a norepinephrine and
serotonin re-uptake inhibitor that promotes weight loss
via appetite suppression and increases in resting energy
Table 1 Schedule of major study assessments
Assessment Screening 0 1 2 4 6 8 12 16 20 24
Diagnostic evaluation
Kiddie schedule of affective disorders – present/lifetime X
Aberrant symptom checklist X
Wechsler abbreviated scale of intelligence X
Family history X
Medical history X
Urine drug screen X
Psychiatric stability (blinded rating)
Clinical global impression – severity and improvement scales X X X
Brief psychiatric rating scale for children X X X
Major metabolic assessments
Weight, height (body mass index z-score) X X X X X X X X X X X
Waist circumference X X X X
Fasting glucose, insulin X X X X
Optional OGTT X X X
HDL, LDL, triglycerides X X X
DEXA X X X
Metabolic syndrome X X X
Medication tracking
Pill count (study drug) and self-report X X X X X X X X X
Drug level (SGA, metformin)* X X X
Review of co-prescribed and OTC medication
Adverse event/safety monitoring
Barnes Akathisia scale X X X X X X X X X X X
Simpson Angus extrapyramidal symptoms scale X X X X X X X X X X X
Abnormal involuntary movement scale X X X
ECG X X
Urine pregnancy (females) X X X X X X X X
HLE review X X X X X X X X X X
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IMPACT study because of potential for adverse CNS ef-
fects, and it subsequently was withdrawn from the US
market in 2010 because of increased risk of heart attack
and stroke in adults [35]. Orlistat is an enteric lipase in-
hibitor [36]. It was not selected because of concerns that
adherence may be hindered by adverse effects, including
fecal incontinence [37], as well as by the complexity of
the medication regimen, i.e., it is recommended to ad-
minister a multi-vitamin at least 2 hours apart from
orlistat and to use this medication up to three times a
day with meals [38].
Topiramate and metformin have been studied specific-
ally for antipsychotic-induced weight gain in adults.
Topiramate is an antiepileptic agent that has FDA
pediatric approval down to age 2 for seizure treatment
[39]. It is also used for off-label treatment of mooddisorders, with the frequently reported side effect of de-
creased appetite/weight loss. A review by Ellinger et al.
[40] reported topiramate was superior to placebo in
three adult RCT’s for either weight loss or BMI outcome
(in this study the topiramate goup had stabilization of
BMI rather than significant reduction in BMI compared
to BMI increase in placebo group). However, concerns
about topirimate use include potential drug interaction
(25% decrease in risperidone concentrations), trouble-
some neurologic adverse events (paresthesias reported
more commonly in the topiramate treated groups in two
of the trials), and the 2008 FDA warning about increased
risk of suicidal behavior or ideation among patients tak-
ing antiepileptic medications [40].
Metformin was selected as the weight loss agent for
the IMPACT study. Metformin decreases hepatic gluco-
neogenesis and improves insulin sensitivity in the liver
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treatment of type 2 diabetes in youth ≥10 years old [42].
The potential side effect of hypoglycemia secondary to
metformin is rare because metformin does not stimulate
insulin production, and there have been no published
pediatric cases of lactic acidosis or increase in serum lac-
tic acid associated with therapeutic doses [43]. A recent
review [44] reported on 13 published trials, including 2
pediatric and 6 adult RCTs, of metformin to manage or
prevent antipsychotic induced weight gain, which the
authors summarized as being associated with modest
weight loss demonstrated in mostly short term trials.
Another systematic review and meta-analysis on the ef-
fect of metfomin treatment on antipsychotic-induced
weight gain [45] reported weight change compared with
placebo as −4.8% in adults and −4.1% in children, al-
though this analysis only included two pediatric studies.
One study was a 12-week RCT in which youth treated
with risperidone were augmented with metformin or
placebo, and both groups showed significant changes in
weight and BMI, however the study included only 32
youth [46]. The other pediatric study was a 16-week
RCT examining metformin co-treatment for 10–17 year
old youth (n = 38) prescribed olanzapine, risperidone, or
quetiapine [47]. There were significant differences in
weight change between the metformin and placebo
treated groups, but the metformin group did not experi-
ence significant weight loss; i.e., the placebo treated
group continued to gain weight while the metformin
group maintained a stable weight.
Control condition
All participants receive healthy lifestyle education. Be-
cause of the clear health risks of pediatric overweight
and obesity, it would be unethical to withhold non-
pharmacologic interventions for six months during the
course of the study. When the IMPACT study was ini-
tially proposed, grant reviewers raised concern about
funding an intensive psychosocial intervention (e.g. diet
and activity interventions at a weight management cen-
ter) because there was no substantial evidence base that
this type of intervention would be effective for mentally
ill youth receiving antipsychotic medication. Another
concern was the potential high burden of frequent and
long study visits for patients receiving lifestyle interven-
tion plus pharmacologic intervention, and the possible
increased parent–child conflict with a highly restrictive
dietary or physical activity intervention.
The basic healthy lifestyle education employed in
IMPACT follows stage 1 of the American Medical As-
sociation pediatric weight loss guidelines (http://www.
ama-assn.org//ama1/pub/upload/mm/433/ped_obesity_
recs.pdf ). This educational program can be administered
by a prescriber or non-clinician and can be easilyimplemented in a mental health outpatient setting, even
with time constraints. The duration of the lifestyle educa-
tion is consistent with guidelines from the 2009 Schizo-
phrenia Patient Outcomes Research Team report [48] that
indicates such an intervention should occur for at least
3 months. To our knowledge, the AMA pediatric weight
loss guidelines have not been studied in a pediatric weight
loss trial for youth with mental illness. Stage 1 and stage 2
guidelines are provided by the AMA.
Stage 1 guidelines focus on education about healthy
diet (e.g. eat breakfast daily) and activity habits and can
be implemented by a non-clinician. HLE is advanced to
Stage 2 guidelines if he/she gains 7% of baseline weight.
Stage 2 guidelines address the following:
1. Eating habits: Increased structure of daily meals and
snacks.
2. Food consumption: Develop a balanced diet with
low amounts of energy dense foods,
3. Physical activity: Supervised active play 60 minutes
per day, limit sedentary activity involving electronic
devices, such as television or computer to <1 hour
per day
4. Monitoring of food consumption and activity by
parent or child and provider.Specific aims and design
IMPACT is a 6-month, multi-site study involving an ini-
tial screening phase to assess eligibility followed by
24 weeks of randomly assigned open-label treatment
and monitoring (Figure 1). This study was approved by
the Institutional Review Boards at the four sites.Specific aims and hypotheses
The primary aim is to determine if each of the pharma-
cologic interventions (switch antipsychotic; add metfor-
min) results in greater weight loss, as measured by BMI
z-score change over 6 months, compared to the control
condition (healthy lifestyle education). As part of sec-
ondary analyses, weight loss will also be examined as 6-
month change in BMI percentile, absolute body weight,
percent body weight, and total body fat assessed with
Dual-Energy X-Ray Absorptiometry (DEXA). We hy-
pothesize that mean change in BMI z-score and body fat
mass, as a percent of baseline body fat mass, will be re-
duced over six months in each of the treatment groups
compared to the control group.
The first secondary aim is to determine if the two
medication strategies result in greater improvement in
metabolic measures, including insulin resistance, triglycer-
ides, LDL cholesterol, and point prevalence of metabolic
syndrome (using adolescent criteria [49]), compared to the
control condition. We hypothesize that these metabolic
Figure 1 Screening to randomization flow chart. Note: HLE = Healthy Lifestyle Education.
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compared to the control group.
The second secondary aim is to establish whether the
proportion of subjects discontinuing treatment is lower
in each pharmacologic group compared to the control
group. Exploratory analyses will examine the proportion
of subjects in each group who discontinue assigned
treatment (HLE, or HLE plus metformin or switch anti-
psychotic) because of 1) psychiatric symptoms and 2)
weight or metabolic reasons. We hypothesize that fewer
participants will discontinue treatment in each of the
treatment groups compared to the control group since
we anticipate that lifestyle education may not be inten-
sive enough to promote weight loss while the child con-
tinues on antipsychotic treatment. We recognize that
antipsychotic switch assignment has a risk of de-
stabilizing psychiatric symptoms, however our protocol
allows for a gradual cross-over titration and flexible dos-
ing to minimize adverse events during the medication
switch.
The most important exploratory analyses will compare
the two pharmacologic intervention groups with respect
to each of the primary and secondary aims. We
hypothesize that the metformin group will have greater
reduction in insulin resistance compared to the switch
antipsychotic group, but that the switch antipsychotic
group will have greater reduction in triglycerides than
the metformin group.
We hypothesize that the metformin group will have a
greater reduction in insulin resistance compared to the
switch antipsychotic group because metformin is a dia-
betes medication that is specifically used to improve in-
sulin sensitivity. This medication is not known, however,
to have specific effects on lipid profile. Thus, we antici-
pate that removing the offending agent (i.e. the anti-
psychotic causing the weight gain) in the switch arm will
be more effective in reducing abnormal triglycerides
than metformin.Study design
Participant sample
Eligibility criteria identify youth aged 8–19 years who have
benefited enough from antipsychotic treatment to justify
ongoing treatment (i.e., achieved psychiatric stability – for
definition, see Table 2), but who are also at greatest risk for
harm from SGA related weight gain. Only youth who: 1)
meet CDC criteria for being “overweight” (i.e., 85th- < 95th
BMI percentile) or “obese” (i.e., >/=95th BMI percentile),
and 2) have been identified by both their caregiver and
clinician as having experienced “substantial weight gain”
during SGA treatment in the past 3 years, are eligible.
These pediatric patients have a compelling need for more
intensive side effect monitoring. Also, their current vul-
nerability to obesity-related health problems balances the
risk of being randomized to an intervention that is not yet
widely used in child psychiatric clinical settings (i.e.,
addition of metformin). Full inclusion and exclusion cri-
teria are presented in Tables 2 and 3.
We have operationalized “substantial weight gain” to
be approximately equivalent to at least 10% of baseline
weight. We allow some flexibility in this determination
because of challenges in obtaining precise and accurate
clinical weight records (e.g. challenges weighing a child
who may have developmental delay and hyperactivity be-
havioral problems; child may have been weighed on dif-
ferent scales using different procedures over the course
of antipsychotic treatment, etc.). When a child’s weight
is measured at the screening visit and over the course of
the study, we have systematic, study-wide procedures
(e.g. same type of scale used; height measured three
times to calculate sex- and age-adjusted BMI percen-
tiles; removal of shoes and added layers of clothing like a
jacket are removed prior to measurement) to improve the
accuracy of weight and ability to compare weights across
sites.
Of note, two conditions are permitted as part of the
eligibility criteria to maintain generalizability of the
Table 2 Inclusion criteria and rationale
Criterion Rationale
Ages 8 to 19 years Even young children are frequently treated with SGAs and experience severe
weight gain. The FDA has approved metformin for use in type 2 diabetes in
children≥ 10 years, it appears 8 year olds could safely use metformin based
on available toxicology literature (Spiller et al. 2000; Benavides et al. 2005),
use in previous clinical trials (Ibanez et al. 2004; Lutjens and Smit 1977), and
advice from our pediatric endocrinology consultant.
Primary DSM-IV diagnosis of Early Onset Schizophrenia Spectrum disoder,
Bipolar Spectrum disorder, Major Depression with psychotic features,
Major Depressive Disorder (only for participants aged 18–19 years),
or Autism with irritability
Most diagnoses or symptom clusters for which a SGA is prescribed in
clinical practice are included to enhance ecological validity.
Clinically stable on current treatment regimen for≥ 30 days Stability is required to reduce risk of psychiatric decompensation
Stable dose of current SGA and psychotropic co-medications
for≥ 30 days
BMI ≥ 85th percentile for age and gender (i.e., at least “at risk
for overweight”)
Youth at greatest risk for harm from SGA weight gain need intensive side
effect monitoring. Current vulnerability to overweight/obesity-related
health problems balances the risk of being randomized to an
intervention that is not yet widely used in child psychiatry clinical
settings (i.e. addition of metformin).
Substantial weight gain over the previous 3 years, while taking
a SGA (aripiprazole, asenapine, iloperidone, lurasidone, olanzapine,
paliperidone, quetiapine, risperidone, or ziprasidone)
All SGAs other than clozapine were included because all have been
associated with substantial weight gain Clozapine was not included
because of unique benefits and it is generally reserved for youth with
severe illness that has not been adequately controlled with other
antipsychotics.
Sexually active girls must agree to use two effective forms of birth
control (i.e., hormonal or spermicidal and barrier) or be abstinent
Risk of study agents to unborn babies.
Participant has a primary caretaker (defined as parent(s), close relative
functioning in loco parentis, legal guardian, or foster parent) who has
known the child well for at least 6 months before study entry
Legal authority to make medical decisions including participation in
research study. Ability to accurately report on past and current functioning.
Primary caretaker is able to participate in study appointments as
is clinically indicated.
Most participants are minor children.
Ability of child to participate in all aspects of the protocol per
investigator clinical judgment.
Child must demonstrate awareness of study procedures and assent
to participate.
After considering all aspects of study participation, including random
assignment, guardian and the child must agree (legally consent and
assent) to participation
Study participation is voluntary but requires consent.
Reeves et al. Child and Adolescent Psychiatry and Mental Health 2013, 7:31 Page 7 of 14
http://www.capmh.com/content/7/1/31findings to a typical child psychiatry clinical population.
First, we allow for ongoing stable treatment with either a
stimulant medication and/or valproate/valproic acid.
Both of these medications are known to effect weight, but
we did not exclude them because they are commonly pre-
scribed to youth receiving antipsychotic medication. We
monitor adherence to stimulants and valproate/valproic
acid for youth receiving these medications at each study
visit along with adherence of antipsychotic medication
and study medication. We also restrict the total number
of psychiatric medications permitted (3 medications total,
including antipsychotic medication or 4 medications total,
if 2 are prescribed for ADHD). Secondly, in addition to in-
cluding diagnoses that either have a pediatric or adult ap-
proved indication, we include youth receiving off-label
antipsychotic treatment for chronic mood dysregulation.
Chronic mood dysregulation is operationalized using the
Leibenluft [50] criteria for Severe Mood Dysregulation
(SMD). Each case is reviewed by the PI steering commit-
tee to provide final approval for randomization based onthe eligibility criteria and clinical status and stability over
the screening period.
Randomization
Eligible participants are randomly assigned to one of the
three treatment conditions using a central, computer-
generated randomization schedule developed and ad-
ministered by the Data Center (DC). Randomizations is
stratified for current SGA (risperidone, aripiprazole (the
two largest expected groups) or “other antipsychotic”)
and diagnosis (1. Early Onset Schizophrenia Spectrum
or 2. Bipolar Disorder, Severe Mood Dysregulation,
psychotic or non-psychotic depression, or irritability as-
sociated with autism). We decided to stratify randomiza-
tion between the two major diagnostic groups, in order
to account for potential differences in sensitivity to
weight gain and in co-medications. In addition, we
stratified by the two baseline SGAs that we expected to
produce the largest groups, risperidone, aripiprazole and
“other antipsychotic”, as the weight gain potential and
Table 3 Exclusion criteria
Eligibility screening information Exclusion criteria
Current medication regimen* 1. Any medication that would significantly alter glucose, insulin, or lipid levels.
2. Treatment with >1 antipsychotic medication.
3. Treatment with >3 total psychiatric medications (exception: 4 total permitted if 2 are ADHD drugs)
Screening labs** 4. Fasting glucose >125 mg/dL
5. Positive urine toxicology screen
6. Serum creatinine ≥ 1.3 mg/dL
7. Independent pediatric consultation is required if glucose 100-125 mg/dL; triglycerides >300 mg/dL,
total cholesterol >300 mg/dL, ALT>174 or 3X upper limit normal to determine if study participation
is appropriate
Somatic health conditions*** 8. Any major neurological or medical illness that affects weight, requires a prohibited systemic medication,
or prohibits physical activity/use of AMA weight loss guidelines.
Psychiatric diagnosis 9. Substance dependence disorder (except tobacco dependence) in the past month
10. Current or lifetime diagnosis of anorexia nervosa or bulimia nervosa
11. IQ <55
Medication history 12. Known hypersensitivity to aripiprazole, perphenazine, or metformin
13. Prior trials of aripiprazole and perphenzine that were >2 weeks and stopped because of efficacy or
tolerability concerns
14. Psychiatric medication or dosage change within the past 30 days.
Additional safety concerns 15. Significant risk of dangerousness to self or others
16. Ongoing or previously undisclosed child abuse requiring new social service intervention.
Caregiver considerations 17. Caregiver unable to participate in assessments or has not known child at least 6 months
18. Caregiver or child have language issue that makes them unable to complete assessments
Female participants 19. Pregnant, nursing, or sexually active and unwilling to comply with double method contraceptive
*Antipsychotic medication, stimulant medication, and divalproex sodium are permitted. Prohibited medications include, but are not limited to: insulin, systemic
steroids, topiramate, sibutramine, orlistat, metformin, amantadine, vitamin E (other than in standard multivitamins), statins, and anti-hypertensive medication.
Exception: orlistat and amantadine are permitted if taken for >1 year without weight loss.
**Laboratory tests are repeated for confirmation if they are abnormal.
***Medical conditions that lead to exclusion include, but are not limited to, diabetes, unstable thyroid disease, chronic renal failure.
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leading to potentially different magnitudes of change in
response to the randomized treatment.
Treatments
Healthy lifestyle education (all subjects)
All participants in the study receive the healthy lifestyle
education following the stage 1 of the 2007 American
Medical Association guidelines for treatment of pediatric
obesity, which provides guidance on healthy eating
habits and activities. Participants advance to stage 2 if
they gain >7% of their baseline body weight during the
conduct of the study to minimize human subject con-
cerns. Stage 2 increases supervision of activity and food
intake and also reduces sedentary activity associated
with television/computer viewing time.
Switch antipsychotic
Youth randomized to this condition have a switch in
their antipsychotic treatment to an antipsychotic medica-
tion, with a lower metabolic risk profile, i.e., aripiprazole
or perphenazine. Antipsychotic switch occurs in a gradualplateau cross over design [51] with flexible dosing (Table 4
and Table 5). The first line switch agent is aripiprazole, the
second switch agent is perphenazine. Youth receive
aripiprazole if they have never been treated with this agent
or if they had a prior inadequate trial without inefficacy or
intolerability; otherwise, they are treated with perphena-
zine. Participants who take perphenazine are prescribed
benztropine, 0.5 mg twice a day if they are titrated to a
dose >8 mg. This dose of benztropine may be adjusted (in-
creased or discontinued) after it is initiated based on pre-
scriber clinical judgment.
Metformin treatment
Metformin is administered using a flexible dosing titra-
tion schedule over 4–6 weeks (see Table 6 for general
guidelines on dosing schedule and target dose based on
two weight groups). The dose is maintained or lowered
based on side effects. Youth who experience significant
side effects are offered the extended release formulation
of metformin, which has a lower incidence of gastro-
intestinal side effects. Families are provided with infor-
mational handouts describing potential drug interactions
Table 4 Recommended dose equivalency for switch
condition
Entry SGA Switch to aripiprazole Switch to perphenazine
Aripiprazole – Dose X 1.33
Asenapine Dose X 1.5 Dose X 2
Iloperidone Dose X 1.25 Dose X 1.75
Lurasidone Dose X 0.25 Dose X 0.35
Olanzapine Dose X 1.5 Dose X 2
Paliperidone Dose X 2.5 Dose X 3.33
Quetiapine Dose X 0.1 Dose X 0.13
Risperidone Dose X 4 Dose X 5
Ziprasidone Dose X 0.125 Dose X 0.17
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formin dosing reaches steady state target levels before
key outcomes are assessed at Week 12.
Control condition
Participants randomized to the control condition receive
healthy lifestyle education only, and no changes are
made to their medication.
Measures and assessment of outcomes
Assessment time points are indicated in Table 6. There
are 10 in-person visits, at 0, 1, 2, 4, 6, 8 and 12, 16, 20
and 24 weeks. In addition, there are telephone contacts
during the first 11 weeks when no regular in-person visit
is scheduled, i.e., at weeks 3, 5, 7, 9, 10 and 11. The
major metabolic assessments occur at baseline, 12 weeks,
and 24 weeks.
The primary outcome measure is the BMI z-score
change (from baseline to week 24), which requires meas-
urement of height and weight. BMI z-scores adjust for
age- and gender-appropriate developmental changes.
Further, BMI z-scores are continuous measures, in con-
trast to BMI percentiles, which are capped at the upper
and lower end.
DEXA scan is used to measure change in total fat
mass. This measurement was selected instead of percentTable 5 Recommended open-label switch titration dosing
Entry SGA Aripiprazole Perphenazine
Week 0 100% 2 mg 4 mg
Week 1 100% 5 mg 8 mg
Week 2 100% 10 mg 12 mg
Week 3 75% 15 mg 16 mg
Week 4 50% 20 mg 24 mg
Week 5 25% 25 mg 28 mg
Week 6 (through week 24) 0% 30 mg* 32 mg*
*This target dose varies based on dose equivalency calculation (Table 5)
(Target dose based on dose equivalency calculation).body fat for two reasons: 1) smaller changes in total
body fat mass can be detected than in percent body fat,
thus the precision is greater, and 2) weight loss is clinic-
ally significant even if it equally affects fat and fat-free
tissues.
All metabolic laboratory values obtained at the main
visits (baseline, week 12, week 24) are obtained after an
overnight fast of at least 8 hours. Glucose, insulin, tri-
glycerides, total cholesterol, high-density lipoprotein
(HDL)- cholesterol, and low-density lipoprotein (LDL)-
cholesterol are analyzed centrally at the Mid-Atlantic
Nutrition and Obesity Research Center at the University
of Maryland School of Medicine. An oral glucose toler-
ance test (OGTT), the more definitive test of insulin
sensitivity, was not required for all patients based on our
experience that some youth would have difficulty tolerat-
ing this lengthy procedure but it was offered as an op-
tional test. Thus, all participants will have insulin
sensitivity measured by a fasting blood draw, and a sub-
group will also have insulin sensitivity measured by an
OGTT. We will analyze the sub-group of participants
who completed both measurements separately to (1) as-
sess correlation between the fasting blood draw and
OGTT insulin sensitivity measurements; and (2) to com-
pare OGTT derived insulin sensitivity results for the
three study arms.
Medication adherence
For all patients, parent/patient self-report adherence
data are collected regarding all psychotropic medica-
tions, including antipsychotics, stimulants, and depakote
at each medication visit. In addition, for all patients,
antipsychotic blood levels are collected at week 12 and
24. Finally, for participants receiving study medication
(i.e., switch antipsychotic or metformin, information is
also collected by pill count at all medication appointments
and by drug levels of metformin at week 12 and 24.
Statistical methods and analytic plan
The primary aim is to compare the relative efficacy of
two medication strategies (S = switch to lower risk agent,
M =metformin augmentation) versus a control condi-
tion (C = control, current SGA) in reducing BMI z-score.
Analyses will be performed on a modified intent-to-treat
population of patients with a baseline and at least one
follow-up visit, using a mixed model approach to re-
peated measures (MMRM). Change in BMI z-score as
well as in secondary body composition parameters (i.e.,
change in BMI percentile, weight and percent weight
compared to baseline, fat mass, waist circumference) will
be modeled as a function of treatment group, time point,
and treatment-by-time point interaction, with current
SGA and diagnosis as blocking factors. The original
IMPACT data analysis plan treated the individual
Table 6 Recommended open-label metformin (plus multivitamin) AM/PM titration dosing
<50 kg 50-70 kg >70 kg
am / pm am / pm am / pm
Week 0 0 mg / 250 mg 0 mg / 250 mg 0 mg / 500 mg
Week 1 250 mg / 250 mg 250 mg / 250 mg 500 mg / 500 mg
Week 2 250 mg / 500 mg 250 mg / 500 mg 500 mg / 1000 mg
Week 3 250 mg / 500 mg 500 mg / 500 mg 500 mg / 1000 mg
Week 4 500 mg / 500 mg 500 mg / 1000 mg 1000 mg / 1000 mg
Week 5 500 mg / 500 mg 500 mg / 1000 mg 1000 mg / 1000 mg
Week 6 (through week 24) 500 mg / 500 mg 500 mg / 1000 mg 1000 mg / 1000 mg
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control condition and (b) metformin versus control con-
dition as co-primary hypotheses, using a 0.025 (=0.05/2)
significance level via Bonferroni correction for each test.
We also used 90% power, which produced an estimate
of 240 patients required. This initial analysis plan was
reviewed and revised after the first year of recruitment
because of concerns that this approach may be overly
conservative and the sample size may be difficult to
achieve given the challenges of recruiting for this study
(e.g. difficulty recruiting individuals with serious mental
illness who meet the clinical stability criteria). The deci-
sion was made, prior to any data analysis, to re-structure
the hypothesis testing to a two stage procedure, which
reduced the sample size requirements. We will first test
for a treatment group main effect in the three treatment
group model. If this test is significant, we will then per-
form two follow-up tests comparing each of the treat-
ment groups to control. The test of treatment main
effect as well as the two follow-up tests will be conducted
at significance level 0.05, instead of 0.025. This testing
procedure does not inflate the overall experiment-wise
error rate, since if we reject the group null hypothesis, we
know at least one of the group means differs from at least
one of the others. The sample size (132 total, 44 per
group) was chosen to allow at least 80% power for the
follow-up pairwise treatment group comparisons on
change in BMI z-scores. This final sample size does
not adjust for attrition. With respect to change in
BMI z-scores, we hypothesized values of: μC = +0.25,
μM= −0.15, μS = −0.10 based on published [47] and pilot
data. We assumed a standard deviation of 0.58. With re-
spect to change in total fat mass as a percent of baseline
fat mass, we hypothesized values of: μS = +1.0%, μM =
−6.0%, and μC = +18%. . We assumed a standard deviation
of 20%.
The secondary aim is to compare the two medication
strategies to the control condition on changes in metabolic
measures, including glucose, insulin, insulin resistance
(measured as Quantitative Insulin Sensitivity Check Index;
QUICKI and Homeostasis Model of Insulin Resistance;HOMA-IR [52,53]), triglycerides, total cholesterol, LDL-
cholesterol, non-HDL cholesterol, HDL-cholesterol, glu-
cose and metabolic syndrome. In addition, in subjects
undergoing the optional 2-hour OGTT, changes in whole
body insulin sensitivity index (ISI), which utilizes insulin
and glucose levels obtained at 30-minute intervals the
OGTT, will be assessed. ISI will be calculated with the
Matsuda & DeFronzo [54] formula: ISI = 10,000 divided
by the square root of (fasting plasma insulin X fasting
plasma glucose X mean plasma glucose X mean plasma
insulin).
Hypotheses are that insulin sensitivity will be increased
in each of the treatment groups individually compared
to the control group, and that lipid and glucose and in-
sulin levels will be reduced. These hypotheses will be
tested using the same MMRM analyses as the hypoth-
eses for the primary aim using changes in insulin resist-
ance, percent reduction in the lipid and glucose
metabolism parameters, and the same two stage testing
procedure to compare treatment groups. With regard to
metabolic syndrome, we will compare the proportion of
subjects with metabolic syndrome at week 24 in the
treatment groups using logistic regression, with group as
a fixed predictor, SGA, and diagnosis as blocking factors.
Finally, our third aim is to compare each of the treat-
ment conditions individually with the control group with
respect to proportion of subjects discontinuing treat-
ment. This will use a logistic regression, with group as a
fixed predictor, and SGA and diagnosis as blocking fac-
tors. We hypothesize that fewer subjects will discontinue
treatment in the metformin group or in the lower risk
agent group than in control group. We plan to also
examine the proportion of subjects in each group who
discontinue treatment because of 1) psychiatric symp-
toms and 2) weight or metabolic reasons, and to exam-
ine time to discontinuation.
Design weaknesses and limitations
A limitation of the IMPACT study is that it is an open
label trial. Double blinding of all treatments was not
done because of the additional costs to purchase current
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tions (six antipsychotics, metformin, and placebo); the
complexity related to changing dose of three different
blinded medications simultaneously; the subsequent like-
lihood of errors and non-compliance; and the burden to
participants associated with taking more and larger cap-
sules each day. We did not feel that double blinding was
necessary because the likelihood that our primary out-
come measure, BMI z-score change, would be affected
by bias is extremely low. Only BPRS-C and CGI ratings
are likely to be influenced by open treatment. To pro-
vide adequate protection against bias, single-blind, inde-
pendent evaluation of psychiatric symptomatology were
included for these measures.
Another weakness of the study is that the healthy life-
style intervention used for the control condition offered
only basic educational support. It is possible that a more
intensive intervention, including a supervised exercise
component and/or more intensive diet monitoring, may
be more effective in promoting weight loss than pharma-
cologic interventions. However, we sought to test inter-
ventions that could be easily administered in a mental
health setting and would not require additional nutri-
tional or other specialist expertise.
Finally, another limitation is that the oral glucose toler-
ance test was offered as an optional assessment. All partic-
ipants had measurement of insulin sensitivity (using
fasting glucose and insulin), but the more sensitive meas-
ure of insulin sensitivity (OGTT) was not required because
of the concerns about burden of testing on participant.
The study included youth as young as age 8, and the two
hour OGTT required children to fast until the metabolic
blood work was completed. The measurements selected
(QUICKI and HOMA-IR) to measure insulin sensitivity in
all participants were done based on consultation with our
study-wide and site endocrinology experts.
Safety & ethical considerations
Important safety and ethical concerns addressed in the
study design focus on safeguards to ensure that (1) the
risk to benefit ratio for the individual patient is appropri-
ate to continue antipsychotic treatment for six months;
(2) stopping criteria are established for youth who ex-
perience psychiatric de-stabilization; and (3) increased
lifestyle interventions are permitted for those who con-
tinue to gain weight.
To insure that an individual patient is appropriate for
continued antipsychotic treatment, each case must be
approved by a PI steering committee prior to enroll-
ment. The diagnostic evaluation, clinical laboratory stud-
ies, and the patient’s current functioning are reviewed.
For patients who continue to gain weight during the
trial, additional healthy lifestyle intervention is provided.
For youth who gain >5% baseline weight, an additionalsession is scheduled to review stage 1 AMA guidelines.
For youth who gain >7% baseline weight, the stage 2
AMA guidelines are implemented by the pharmaco-
therapist. This more intensive intervention includes
greater parental supervision of child diet and activity and
goal setting for weight loss.
Investigators consult with a pediatric endocrinologist,
and participants will be referred to a pediatrician if they
cross any of the following thresholds and maintain them
over two weeks:
 Substantial weight gain (i.e., ≥10% increase in
baseline weight);
 diabetes mellitus (fasting glucose > 125 mg/dL on two
occasions or GTT 120 min glucose ≥200 mg/dL);
 dyslipidemia with triglyceride or cholesterol levels >
450 mg/dL.
Children must be withdrawn from the study and be re-
ferred for individualized care in the community in any of
3 situations: 1) participant or guardian request, 2) judg-
ment of the independent pediatrician or consulting
pediatric endocrinologist that metabolic problems re-
quire treatment beyond that which the child is currently
receiving in the study, or 3) significant worsening of psy-
chiatric symptoms unless the PT and/or family request
review by the study wide PI steering committee. Signifi-
cant worsening of psychiatric symptoms is operationalized
as IE rating of CGI-I of 6 – “much worse” or 7 – “very
much worse” on two successive occasions over a period of
at least two weeks.
There are no defined stopping criteria for weight gain
or the development of metabolic problems. We decided
to use the clinical consultation from an independent
pediatric expert, rather than setting a predetermined
stopping threshold because there are several consider-
ations that need to be assessed to determine if a patient
should seek alternative care. For example, families may
not have access to alternative weight loss programs that
can accommodate the child’s mental health needs (e.g.
youth with developmental delay or aggressive behavior
problems). Secondly, it may not be feasible (e.g. added ap-
pointment burden, travel time) for families to attend a
weight loss program that is not integrated with the child’s
mental health care. Finally, multiple clinical factors (e.g.
family history, duration of metabolic abnormalities)
should be evaluated to consider the child’s unique risk for
diabetes and heart disease. Thus, we allowed for the deci-
sion about study discontinuation to be made clinically, ra-
ther than by a single strict metabolic stopping criterion.
Conclusion
Child psychiatry clinical trials have traditionally focused
on efficacy of medications to treat mental illness.
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by focusing on interventions to manage clinically rele-
vant adverse effects. Adverse effect concerns are an im-
portant priority for research because of their short-term
impact on treatment adherence and long term impact
on a child’s development and risk for future health prob-
lems. SGA induced weight gain is a also major public
health concern because SGA prescribing to youth is
expected to increase with growing uses of these medica-
tions in pediatric treatment.
In addition to the focus on side effect concerns, there
are several noteworthy aspects of the IMPACT study de-
sign. First, the study duration of six months is signifi-
cantly longer than typical acute treatment studies. This
longer time frame allows for more comprehensive as-
sessment of psychiatric stability and is a more appropri-
ate follow-up period for weight loss interventions, which
often report that acute weight loss reverses over time.
Secondly, the eligibility criteria include youth who are
often excluded from traditional clinical trials, improving
the generalizability of study results to real world prac-
tice. For example, youth with mild mental retardation,
bipolar illness, co-occurring mental illness, and/or com-
monly co-prescribed pharmacologic agents have not
been excluded. Thirdly, the state of the art metabolic as-
sessment techniques, including body composition analysis
and insulin sensitivity testing, allows for comprehensive
and developmentally appropriate assessment of early car-
diovascular disease and type 2 diabetes risk. With FDA ap-
provals for pediatric antipsychotic treatment down to age
5–6 years old for some SGA medications, there is a grow-
ing need to identify metabolic changes that can be
detected in young children (e.g. insulin sensitivity changes
that proceed over diabetes).
One important challenge of the IMPACT study design
has been the rapid changes in available medicines and
prescribing trends. As described, increasing use of
aripiprazole and discontinuation of molindone prompted
design changes to the in-progress study. Moreover, three
new antipsychotic medications have been made available
in the US market since the IMPACT study has been ini-
tiated, namely asenapine, lurasidone, and iloperidone.
Off label medication treatments in child psychiatry are
common, and changes in clinical practice and standard
of care sometimes precede pediatric studies to establish
evidence base for treatments. It is unclear at this point if
any of these new agents will have a more favorable risk
to benefit ratio for the switch strategy than either
aripiprazole or perphenazine. This rapidly changing psy-
chopharmacology landscape raises important issues for
study in terms of clinical treatment (e.g. factors that lead
to rapid adoption of medication in pediatric treatment
prior to established pediatric evidence base) as well as
considerations for funding agencies in terms of thetimeline and flexibility in conducting research so that
the questions developed when the study is proposed re-
main relevant to real world prescribing practices when
the results are available.
It is important to note that discontinuing antipsychotic
treatment altogether is an option that may be considered
clinically for youth with SGA associated weight gain
based on patient/parent preference, severity of adverse
events, and current psychiatric stability/symptom profile.
Since most youth prescribed antipsychotic medication
are being treated for non-psychotic conditions, it is ap-
propriate to exhaust first line medication and psycho-
social treatments before even initiating SGA medication
and to monitor for changes in the risk to benefit ratio of
SGA medication over the course of treatment. In our
sample, most referred youth had a history of significant
safety concerns (e.g. severe aggression, self-harm), high-
level service utilization (e.g. inpatient, emergency room
services), and recurrent episodes of mental illness prior
to SGA treatment. Thus, the risk to benefit ratio of
treatment options needs to take into consideration both
metabolic and psychiatric health concerns.
In summary, results from the IMPACT study are
expected to provide important and currently lacking in-
formation that can help guide clinical decision making
aimed at improving both psychiatric and physical health
of youth with severe mental disorders.
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